- Home
- FURY vs OTLK Comparison
FURY vs OTLK Comparison
Compare FURY & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FURY | OTLK |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 29.2M |
| IPO Year | 2011 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FURY | OTLK |
|---|---|---|
| Price | $0.59 | $0.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $1.70 | ★ $2.50 |
| AVG Volume (30 Days) | 342.1K | ★ 4.4M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.16 |
| 52 Week High | $1.02 | $3.39 |
Technical Indicators
Market Signals| Indicator | FURY | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 52.61 |
| Support Level | $0.58 | $0.17 |
| Resistance Level | $0.64 | $0.46 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 21.59 | 63.00 |
Price Performance
Historical ComparisonAbout FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.